Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV

被引：161

作者：

Saussele, Susanne ^{[1
]}

Lauseker, Michael ^{[2
]}

Gratwohl, Alois ^{[3
]}

Beelen, Dietrich W. ^{[4
]}

Bunjes, Donald ^{[5
]}

Schwerdtfeger, Rainer ^{[6
]}

Kolb, Hans-Jochem ^{[7
]}

Ho, Anthony D. ^{[8
]}

Falge, Christiane ^{[9
]}

Holler, Ernst ^{[10
]}

Schlimok, Guenter ^{[11
]}

Zander, Axel R. ^{[12
]}

Arnold, Renate ^{[13
]}

Kanz, Lothar ^{[14
]}

Dengler, Robert ^{[15
]}

Haferlach, Claudia ^{[16
]}

Schlegelberger, Brigitte ^{[17
]}

Pfirrmann, Markus ^{[2
]}

Mueller, Martin C. ^{[1
]}

Schnittger, Susanne ^{[16
]}

Leitner, Armin ^{[1
]}

Pletsch, Nadine ^{[1
]}

Hochhaus, Andreas ^{[1
,18
]}

Hasford, Joerg ^{[2
]}

Hehlmann, Ruediger ^{[1
]}

机构：

[1] Heidelberg Univ, Med Fak Mannheim, Med Klin 3, D-68169 Mannheim, Germany

[2] Univ Munich, Inst Med Informat Verarbeitung IBE, D-80539 Munich, Germany

[3] Univ Spital Basel, Basel, Switzerland

[4] Univ Duisburg Essen, Univ Klinikum, Klin Knochenmarktransplantat, Duisburg, Germany

[5] Univ Ulm Klinikum, Innere Med Klin 3, Ulm, Germany

[6] Deutsch Klin Diagnost, Zentrum Knochenmarktransplantat, D-6200 Wiesbaden, Germany

[7] Univ Munich, Klinikum Grosshadern, Med Klin 3, D-8000 Munich, Germany

[8] Heidelberg Univ, Med Klin 5, Heidelberg, Germany

[9] Klinikum Nord, Nurnberg, Germany

[10] Univ Klinikum Regensburg, Regensburg, Germany

[11] Zent Klinikum, Med Klin 2, Augsburg, Germany

[12] Univ Klinikum Hamburg Eppendorf, Zentrum Knochenmarktransplantat, Hamburg, Germany

[13] Charite, D-13353 Berlin, Germany

[14] Univ Klinikum Tubingen, Tubingen, Germany

[15] Hamatol Onkol Praxis, Regensburg, Germany

[16] Munich Leukemia Lab, Munich, Germany

[17] Hannover Med Sch, Inst Zell & Mol Pathol, D-30623 Hannover, Germany

[18] Univ Klinikum, Klin Innere Med 2, Jena, Germany

来源：

BLOOD | 2010年 / 115卷 / 10期

关键词：

CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE INHIBITORS; BCR-ABL TRANSCRIPTS; THERAPY; SURVIVAL; DISEASE; RECOMMENDATIONS; TOXICITY; MESYLATE;

D O I：

10.1182/blood-2009-08-237115

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The role of allogeneic stem cell transplantation in chronic myeloid leukemia is being reevaluated. Whereas drug treatment has been shown to be superior in first-line treatment, data on allogeneic hematopoietic stem cell transplantation (allo SCT) as second-line therapy after imatinib failure are scarce. Using an interim safety analysis of the randomized German CML Study IV designed to optimize imatinib therapy by combination, dose escalation, and transplantation, we here report on 84 patients who underwent consecutive transplantation according to predefined criteria (low European Group for Blood and Marrow Transplantation [EBMT] score, imatinib failure, and advanced disease). Three-year survival after transplantation of 56 patients in chronic phase was 91% (median follow-up: 30 months). Transplantation-related mortality was 8%. In a matched pair comparison of patients who received a transplant and those who did not, survival was not different. Three-year survival after transplantation of 28 patients in advanced phase was 59%. Eighty-eight percent of patients who received a transplant achieved complete molecular remissions. We conclude that allo SCT could become the preferred second-line option after imatinib failure for suitable patients with a donor. The study is registered at the National Institutes of Health, http://clinicaltrials.gov:NCT00055874. (Blood. 2010; 115: 1880-1885)

引用

页码：1880 / 1885

页数：6

共 28 条

[1] Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet [J].

Baccarani, Michele ;

Saglio, Giuseppe ;

Goldman, John ;

Hochhaus, Andreas ;

Simonsson, Bengt ;

Appelbaum, Frederick ;

Apperley, Jane ;

Cervantes, Francisco ;

Cortes, Jorge ;

Deininger, Michael ;

Gratwohl, Alois ;

Guilhot, Frangois ;

Horowitz, Mary ;

Hughes, Timothy ;

Kantarjian, Hagop ;

Larson, Richard ;

Niederwieser, Dielger ;

Silver, Richard ;

Hehlmann, Rudiger .

BLOOD, 2006, 108 (06) :1809-1820

[2] The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia-a report from the German Registry covering the period from 1998 to 2004 [J].

Bacher, Ulrike ;

Klyuchnikov, Evgeny ;

Zabelina, Tatjana ;

Ottinger, Hellmut ;

Beelen, Dietrich W. ;

Schrezenmeier, Hubert ;

Ehninger, Gerhard ;

Mueller, Carlheinz ;

Berger, Juergen ;

Suttorp, Meinolf ;

Kolb, Hans-Jochem ;

Kroeger, Nicolaus ;

Zander, Axel R. .

ANNALS OF HEMATOLOGY, 2009, 88 (12) :1237-1247

[3]

CROSS NCP, 1993, BLOOD, V82, P1929

[4]

Deininger M, 2006, HAEMATOLOGICA, V91, P452

[5] Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia [J].

Giralt, Sergio A. ;

Arora, Mukta ;

Goldman, John M. ;

Lee, Stephanie J. ;

Maziarz, Richard T. ;

McCarthy, Philip L. ;

Sobocinski, Kathleen A. ;

Horowitz, Mary M. .

BRITISH JOURNAL OF HAEMATOLOGY, 2007, 137 (05) :461-467

[6]

Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.3.CO

[7]

2-F

[8] Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation [J].

Gratwohl, A ;

Hermans, J ;

Goldman, JM ;

Arcese, W ;

Carreras, E ;

Devergie, A ;

Frassoni, F ;

Gahrton, G ;

Kolb, H ;

Niederwieser, D ;

Ruutu, T ;

Vernant, JP ;

de Witte, T ;

Apperley, J .

LANCET, 1998, 352 (9134) :1087-1092

[9]

Gratwohl A, 2006, HAEMATOLOGICA, V91, P513

[10] A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa [J].

Hasford, J ;

Pfirrmann, M ;

Hehlmann, R ;

Allan, NC ;

Baccarani, M ;

Kluin-Nelemans, JC ;

Alimena, G ;

Steegmann, JL ;

Ansari, H .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (11) :850-858

← 1 2 3 →